SCHEMBL16394563

SCHEMBL16394563

CCCCCCCCC=CCCCCCCCC(=O)C(C)(N)C(C)CC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 7/20 0.56
▸ CES1 P23141 2/20 0.56
▸ CYP1A2 P05177 2/20 0.54
▸ CYP2C19 P33261 2/20 0.54
▸ SOAT1 P35610 2/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ MEN1 O00255 1/20 0.54
▸ TP53 P04637 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ TERT O14746 3/20 0.50
▸ PTPN1 P18031 3/20 0.50
▸ PPARG P37231 3/20 0.50
▸ PPARD Q03181 3/20 0.50
▸ PPARA Q07869 3/20 0.50
▸ MAPT P10636 2/20 0.50
▸ BLM P54132 2/20 0.50
▸ HSD17B10 Q99714 2/20 0.50
▸ FABP4 P15090 2/20 0.50
▸ KDM4E B2RXH2 2/20 0.50
▸ GMNN O75496 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28857015 0.87 FAAH (0.58) FAAHCES1CYP1A2CYP2C19SOAT1
SCHEMBL9330785 0.81 FAAH (0.67) FAAHCES1CYP1A2CYP2C19SOAT1
SCHEMBL31280143 0.81 FAAH (0.67) FAAHCES1CYP1A2CYP2C19SOAT1
SCHEMBL21964138 0.80 FAAH (0.65) FAAHCES1CYP1A2CYP2C19SOAT1
SCHEMBL8655383 0.79 FAAH (0.69) FAAHCES1CYP1A2CYP2C19SOAT1
Hydrochloric Acid SCHEMBL7071028 0.79 FAAH (0.59) FAAHCES1CYP1A2CYP2C19SOAT1
SCHEMBL28718283 0.78 FAAH (0.63) FAAHCES1CYP1A2CYP2C19SOAT1
SCHEMBL30446191 0.78 FAAH (0.63) FAAHCES1CYP1A2CYP2C19SOAT1
Hydrochloric Acid SCHEMBL2044461 0.78 FAAH (0.67) FAAHCES1CYP1A2CYP2C19SOAT1
SCHEMBL21751441 0.78 FAAH (0.67) FAAHCES1CYP1A2CYP2C19SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9333254-B2 Long term disease modification using immunostimulatory oligonucleotides DYNAVAX TECHNOLOGIES CORPORATION (US) 2016-05-10 — — US disclosed
US-20150024007-A1 LONG TERM DISEASE MODIFICATION USING IMMUNOSTIMULATORY OLIGONUCLEOTIDES DYNAVAX TECHNOLOGIES CORPORATION 2015-01-22 — — US disclosed
Send feedback